Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy

Tafasitamab is an Fc-modified monoclonal antibody that binds to CD19, a cell-surface antigen that is broadly expressed on various types of B-cell non-Hodgkin’s lymphoma (NHL). Antibody-dependent cellular cytotoxicity (ADCC), a key mode of action of tafasitamab, is mediated through the binding of taf...

Descripción completa

Detalles Bibliográficos
Autores principales: Her, Jung Hyun, Pretscher, Dominik, Patra-Kneuer, Maria, Schanzer, Juergen, Cho, Sung Yoo, Hwang, Yu Kyeong, Hoeres, Timm, Boxhammer, Rainer, Heitmueller, Christina, Wilhelm, Martin, Steidl, Stefan, Endell, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519642/
https://www.ncbi.nlm.nih.gov/pubmed/35348812
http://dx.doi.org/10.1007/s00262-022-03165-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519642/
https://www.ncbi.nlm.nih.gov/pubmed/35348812
http://dx.doi.org/10.1007/s00262-022-03165-w

Ejemplares similares